Figure 3.

Characterization of CNO-induced wakefulness. A, Time-weighted frequency histograms showing the proportion of wake bouts of each duration (WBD) relative to the total amount of wakefulness from ZT12 to ZT17 after CNO or SAL treatment in Gad2-IRES-Cre;R26R-EYFP mice. Asterisks denote significant differences (p < 0.04, n = 9, t test with Bonferroni correction for multiple comparisons). B, Hourly percentage of time spent in W for naïve WT mice injected with CNO or SAL during the inactive phase. C, HθWP in the dark period after CNO or SAL dosing of Gad2-IRES-Cre;R26R-EYFP mice at ZT12. Asterisk denotes a significant difference for the respective hour when a significant treatment × time interaction was found (p = 0.046, n = 9; two-way repeated measures ANOVA, Bonferroni post hoc t test). D, Normalized EEG power spectrum during W averaged from ZT13 to ZT15 after dosing of Gad2-IRES-Cre;R26R-EYFP mice with CNO (red) or SAL (black) at ZT12. E, Mean power for EEG spectral bands of Gad2-IRES-Cre;R26R-EYFP mice after dosing with either CNO or SAL, normalized by baseline. Asterisk denotes a significant difference for the respective band when ANOVA revealed a significant treatment × power band (p = 0.002, n = 9; two-way repeated measures ANOVA, Bonferroni post hoc t test). F, Percentage of time mice spent moving at different speeds from ZT12 to ZT14 during W. G, Example of simultaneous recordings of mean speed per epoch (black trace) and scale-adjusted HθWP (green trace).